Intraocular fluid analysis-guided precision therapy in the treatment of acute retinal necrosis syndrome
Abstract Investigate intraocular fluid testing’s role in ARNs management and prognosis. 46 ARNs patients (49 eyes) treated from 2021 to 2023 were divided into precision (n = 22) and conventional (n = 24) groups based on intraocular fluid testing. Precision group received intravitreal ganciclovir (20...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-04-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-98624-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849713727976243200 |
|---|---|
| author | Xiao Yu Ziqing mao Yuling Zou Yao Zhao Huimin Fan Teng Liu Yiming Lei Hua Zou Zhipeng You |
| author_facet | Xiao Yu Ziqing mao Yuling Zou Yao Zhao Huimin Fan Teng Liu Yiming Lei Hua Zou Zhipeng You |
| author_sort | Xiao Yu |
| collection | DOAJ |
| description | Abstract Investigate intraocular fluid testing’s role in ARNs management and prognosis. 46 ARNs patients (49 eyes) treated from 2021 to 2023 were divided into precision (n = 22) and conventional (n = 24) groups based on intraocular fluid testing. Precision group received intravitreal ganciclovir (20 mg/ml [viral copies < 5 × 106] or 40 mg/ml [> 5 × 106]) twice weekly; conventional group received fixed 20 mg/ml. BCVA, viral copies, cytokines (IL-6, IL-8, IL-10), and biomarkers (VCAM, VEGF, BFGF) were analyzed. No baseline differences in BCVA, IOP, or clinical features between groups (P > 0.05). Precision group showed fewer injections, higher final BCVA, and lower retinal detachment rates (P < 0.05). Viral copies negatively correlated with final BCVA (P < 0.05). In precision group: viral copies positively correlated with injection frequency, IL-6, IL-8, VCAM, BFGF; retinal necrosis extent positively linked to initial/final BCVA but inversely with IL-6, IL-8, and viral load. Conventional group showed retinal necrosis involvement positively correlated with detachment risk (P < 0.05). Intraocular fluid testing optimizes ARNs treatment personalization, improves outcomes, and enhances prognostic evaluation. |
| format | Article |
| id | doaj-art-007b9660bbd848848e4e4e496646817e |
| institution | DOAJ |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-007b9660bbd848848e4e4e496646817e2025-08-20T03:13:54ZengNature PortfolioScientific Reports2045-23222025-04-011511910.1038/s41598-025-98624-6Intraocular fluid analysis-guided precision therapy in the treatment of acute retinal necrosis syndromeXiao Yu0Ziqing mao1Yuling Zou2Yao Zhao3Huimin Fan4Teng Liu5Yiming Lei6Hua Zou7Zhipeng You8The Affiliated Eye Hospital, Jiangxi Medical College, Nanchang UniversityThe Affiliated Eye Hospital, Jiangxi Medical College, Nanchang UniversityThe Affiliated Eye Hospital, Jiangxi Medical College, Nanchang UniversityThe Affiliated Eye Hospital, Jiangxi Medical College, Nanchang UniversityThe Affiliated Eye Hospital, Jiangxi Medical College, Nanchang UniversityThe Affiliated Eye Hospital, Jiangxi Medical College, Nanchang UniversityThe Affiliated Eye Hospital, Jiangxi Medical College, Nanchang UniversityThe Affiliated Eye Hospital, Jiangxi Medical College, Nanchang UniversityThe Affiliated Eye Hospital, Jiangxi Medical College, Nanchang UniversityAbstract Investigate intraocular fluid testing’s role in ARNs management and prognosis. 46 ARNs patients (49 eyes) treated from 2021 to 2023 were divided into precision (n = 22) and conventional (n = 24) groups based on intraocular fluid testing. Precision group received intravitreal ganciclovir (20 mg/ml [viral copies < 5 × 106] or 40 mg/ml [> 5 × 106]) twice weekly; conventional group received fixed 20 mg/ml. BCVA, viral copies, cytokines (IL-6, IL-8, IL-10), and biomarkers (VCAM, VEGF, BFGF) were analyzed. No baseline differences in BCVA, IOP, or clinical features between groups (P > 0.05). Precision group showed fewer injections, higher final BCVA, and lower retinal detachment rates (P < 0.05). Viral copies negatively correlated with final BCVA (P < 0.05). In precision group: viral copies positively correlated with injection frequency, IL-6, IL-8, VCAM, BFGF; retinal necrosis extent positively linked to initial/final BCVA but inversely with IL-6, IL-8, and viral load. Conventional group showed retinal necrosis involvement positively correlated with detachment risk (P < 0.05). Intraocular fluid testing optimizes ARNs treatment personalization, improves outcomes, and enhances prognostic evaluation.https://doi.org/10.1038/s41598-025-98624-6Acute retinal necrosis syndromeIntraocular fluid testingPrognosis evaluationCorrelation analysisPolymerase chain reaction |
| spellingShingle | Xiao Yu Ziqing mao Yuling Zou Yao Zhao Huimin Fan Teng Liu Yiming Lei Hua Zou Zhipeng You Intraocular fluid analysis-guided precision therapy in the treatment of acute retinal necrosis syndrome Scientific Reports Acute retinal necrosis syndrome Intraocular fluid testing Prognosis evaluation Correlation analysis Polymerase chain reaction |
| title | Intraocular fluid analysis-guided precision therapy in the treatment of acute retinal necrosis syndrome |
| title_full | Intraocular fluid analysis-guided precision therapy in the treatment of acute retinal necrosis syndrome |
| title_fullStr | Intraocular fluid analysis-guided precision therapy in the treatment of acute retinal necrosis syndrome |
| title_full_unstemmed | Intraocular fluid analysis-guided precision therapy in the treatment of acute retinal necrosis syndrome |
| title_short | Intraocular fluid analysis-guided precision therapy in the treatment of acute retinal necrosis syndrome |
| title_sort | intraocular fluid analysis guided precision therapy in the treatment of acute retinal necrosis syndrome |
| topic | Acute retinal necrosis syndrome Intraocular fluid testing Prognosis evaluation Correlation analysis Polymerase chain reaction |
| url | https://doi.org/10.1038/s41598-025-98624-6 |
| work_keys_str_mv | AT xiaoyu intraocularfluidanalysisguidedprecisiontherapyinthetreatmentofacuteretinalnecrosissyndrome AT ziqingmao intraocularfluidanalysisguidedprecisiontherapyinthetreatmentofacuteretinalnecrosissyndrome AT yulingzou intraocularfluidanalysisguidedprecisiontherapyinthetreatmentofacuteretinalnecrosissyndrome AT yaozhao intraocularfluidanalysisguidedprecisiontherapyinthetreatmentofacuteretinalnecrosissyndrome AT huiminfan intraocularfluidanalysisguidedprecisiontherapyinthetreatmentofacuteretinalnecrosissyndrome AT tengliu intraocularfluidanalysisguidedprecisiontherapyinthetreatmentofacuteretinalnecrosissyndrome AT yiminglei intraocularfluidanalysisguidedprecisiontherapyinthetreatmentofacuteretinalnecrosissyndrome AT huazou intraocularfluidanalysisguidedprecisiontherapyinthetreatmentofacuteretinalnecrosissyndrome AT zhipengyou intraocularfluidanalysisguidedprecisiontherapyinthetreatmentofacuteretinalnecrosissyndrome |